Certified by Founder
Lodge
GC Therapeutics
start up
United States
- Cambridge, MA
- 24/09/2024
- Series A
- $65,000,000
GC Therapeutics Inc. (GCTx) uses synthetic biology to program patient-derived stem cells into any cell type with best-in-class efficiency (up to 10X), speed (up to 100X) and scalability. We dictate cells fates in a single step and have validated cells for many applications. We have also developed SuperCells™ by tailoring cells for specific diseases.
The core technology of GCTx was conceived, invented and perfected in Professor George Church’s lab at Harvard Medical School. We are a group of passionate biologists and tissue engineers whose goal is to bring this breakthrough approach to patients.
- Industry Biotechnology Research
- Website https://www.gc-tx.com/
- LinkedIn https://www.linkedin.com/company/gctx/
Tolemy Bio | $1,643,411 | (May 13, 2026)
Basata | $21,000,000 | (May 13, 2026)
Corvera (YC W26) | $4,200,000 | (May 13, 2026)
4AM | $4,000,000 | (May 13, 2026)
Ciridae | $20,000,000 | (May 13, 2026)
Sedivention - Freezing the hunger feeling | $3,402,541 | (May 13, 2026)
Meatly | $14,074,996 | (May 13, 2026)
NanoStruct GmbH | $3,050,853 | (May 13, 2026)
Adfin | $18,000,000 | (May 13, 2026)
Boundary | $2,000,000 | (May 13, 2026)
Algorithmiq | $21,122,550 | (May 13, 2026)
Knit Health | $11,600,000 | (May 13, 2026)